Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers - Full Text View

Sponsor:	University Hospital, Angers
Information provided by:	University Hospital, Angers
ClinicalTrials.gov Identifier:	NCT00152724

Purpose

Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.

Condition	Intervention	Phase
Healthy Volunteers	Device: pressure strain system, iontophoresis Drug: scopolamin Drug: emla Drug: capsaicin Drug: aspirin Drug: clopidogrel Drug: celecoxib Drug: indomethacin Drug: acetylcholine Drug: sodium nitroprusside Drug: brethyllium Device: general and local heating	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Diagnostic
Official Title:	Etude de la Reserve Vasomotrice Microcirculatoire cutanée

Resource links provided by NLM:

Drug Information available for: Acetylsalicylic acid Acetylcholine Indomethacin Acetylcholine chloride Sodium nitroprusside Nitroprusside Clopidogrel Clopidogrel Bisulfate Celecoxib Capsaicin

U.S. FDA Resources

Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:

Amplitude of the vasomotor response to stimuli

Secondary Outcome Measures:

Kinetics of the vasomotor response to stimuli

Estimated Enrollment:	85
Study Start Date:	January 1996
Estimated Study Completion Date:	January 2008

Detailed Description:

This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy volunteers with no clinical signs of, or risk factors for, vascular disease

Exclusion Criteria:

Smokers, Pregnancy, Allergy,

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00152724

Contacts

Contact: Pierre ABRAHAM, MD, PhD

(0)2-41-35-46-17 ext 33

piabraham@chu-angers.fr

Locations

France
Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers	Recruiting
Angers, France, 49033
Contact: Pierre ABRAHAM, MD, PhD (0)2-41-35-46-17 ext 33 piabraham@chu-angers.fr

Sponsors and Collaborators

University Hospital, Angers

Investigators

Principal Investigator:

Jean Louis SAUMET, MD - PhD

University Hospital, Angers

More Information

Publications:

Tartas M, Durand S, Koitka A, Bouye P, Saumet JL, Abraham P. Anodal current intensities above 40 microA interfere with current-induced axon-reflex vasodilatation in human skin. J Vasc Res. 2004 May-Jun;41(3):261-7. Epub 2004 May 19.

Durand S, Fromy B, Humeau A, Sigaudo-Roussel D, Saumet JL, Abraham P. Break excitation alone does not explain the delay and amplitude of anodal current-induced vasodilatation in human skin. J Physiol. 2002 Jul 15;542(Pt 2):549-57.

Tartas M, Bouye P, Koitka A, Durand S, Gallois Y, Saumet JL, Abraham P. Early vasodilator response to anodal current application in human is not impaired by cyclooxygenase-2 blockade. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1668-73. Epub 2004 Nov 24.

Durand S, Tartas M, Bouye P, Koitka A, Saumet JL, Abraham P. Prostaglandins participate in the late phase of the vascular response to acetylcholine iontophoresis in humans. J Physiol. 2004 Dec 15;561(Pt 3):811-9. Epub 2004 Oct 21.

Durand S, Fromy B, Tartas M, Jardel A, Saumet JL, Abraham P. Prolonged aspirin inhibition of anodal vasodilation is not due to the trafficking delay of neural mediators. Am J Physiol Regul Integr Comp Physiol. 2003 Jul;285(1):R155-61.

Durand S, Fromy B, Koitka A, Tartas M, Saumet JL, Abraham P. Oral single high-dose aspirin results in a long-lived inhibition of anodal current-induced vasodilatation. Br J Pharmacol. 2002 Oct;137(3):384-90.

Durand S, Fromy B, Bouye P, Saumet JL, Abraham P. Vasodilatation in response to repeated anodal current application in the human skin relies on aspirin-sensitive mechanisms. J Physiol. 2002 Apr 1;540(Pt 1):261-9.

ClinicalTrials.gov Identifier:	NCT00152724 History of Changes
Other Study ID Numbers:	CP96-04
Study First Received:	September 8, 2005
Last Updated:	March 16, 2007
Health Authority:	France: Ministry of Health

Keywords provided by University Hospital, Angers:

Physiology
Microcirculation
Laser-Doppler Flowmetry

Additional relevant MeSH terms:

Acetylcholine
Nitroprusside
Aspirin
Indomethacin
Clopidogrel
Celecoxib
Capsaicin
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics

ClinicalTrials.gov processed this record on February 09, 2012